Clinical Trial Update: The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating calcitriol for systemic lupus erythematosus–associated lupus nephritis with persistent proteinuria has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Calcitriol (calcitriol)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Systemic Lupus Erythematosus, Nephritis | Phase 4 | Status: WITHDRAWN